MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study

BACKGROUND: Chronic visual loss is a disabling feature in patients with multiple sclerosis (MS). It was recently shown that MD1003 (high-dose pharmaceutical-grade biotin or hdPB) may improve disability in patients with progressive MS. OBJECTIVE: The aim of this study was to evaluate whether MD1003 i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:CNS Drugs
Main Authors: Tourbah, Ayman, Gout, Olivier, Vighetto, Alain, Deburghgraeve, Véronique, Pelletier, Jean, Papeix, Caroline, Lebrun-Frenay, Christine, Labauge, Pierre, Brassat, David, Toosy, Ahmed, Laplaud, David-Axel, Outteryck, Olivier, Moreau, Thibault, Debouverie, Marc, Clavelou, Pierre, Heinzlef, Olivier, De Sèze, Jérôme, Defer, Gilles, Sedel, Frédéric, Arndt, Carl
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2018
Assuntos:
Original Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6061426/
https://ncbi.nlm.nih.gov/pubmed/29808469
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40263-018-0528-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados